PRODUCT – Talk Bio

Eli Lilly; Ventyx Biosciences; $1.2 billion; acquisition; NLRP3 inhibitors; VTX3232; VTX2735; inflammatory diseases; oral therapies; cardiometabolic; neuroinflammation; autoimmune diseases

Exclusive: Charles Fuchs departs Roche to become Chief Medical Officer at Tubulis, steering ADC pipeline after $401M Series C

3 weeks ago talkbio0Tagged Antibody-Drug Conjugates, Cambridge office, Charles Fuchs, Chief Medical Officer, genentech, Hematology (discipline), NaPi2b, Neoplasms, pipeline, Roche (company), Series C financing, Solid Neoplasm, therapeutic autologous dendritic cells, TPBG gene, TUB-030, TUB-040, Tubulis

Charles Fuchs; Tubulis; Roche; Genentech; chief medical officer; antibody-drug conjugates; ADC pipeline; TUB-040; TUB-030; Series C financing; oncology; hematology; solid tumors; NaPi2b; 5T4; Cambridge office

OpenAI launches ChatGPT Health as a dedicated, privacy-focused health assistant

3 weeks ago talkbio0Tagged Apple Health, b.well partnership, ChatGPT Health, DNA Integration, Health care facility, health data privacy, HealthBench, Healthcare AI, Medical Records, wellness apps * *

OpenAI; ChatGPT Health; healthcare AI; medical records integration; Apple Health; wellness apps; health data privacy; HealthBench; b.well partnership; AI in healthcare

AstraZeneca Pays $100M Upfront, Up to $2B Total for Jacobio’s Pan-KRAS Inhibitor JAB-23E73

1 month ago talkbio0Tagged Antineoplastic Agents, AstraZeneca, Inhibitor, Jacobio Pharma, milestones, pan-KRAS

AstraZeneca; Jacobio Pharma; JAB-23E73; pan-KRAS inhibitor; cancer drug; licensing deal; $100M upfront; $2B milestones

FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy, Positioning It Against BMS’s Camzyos

1 month ago talkbio0Tagged Aficamten, Approved, Camzyos, Cytokinetics, Hypertrophic obstructive cardiomyopathy, Myers Squibb, Myqorzo, United States Food and Drug Administration

FDA approval; Cytokinetics; Myqorzo; aficamten; obstructive hypertrophic cardiomyopathy; Bristol Myers Squibb; Camzyos

Jim Lang Appointed to the Board of Directors of Halozyme Therapeutics

1 month ago talkbio0Tagged Appointments, Bench International, Biological Factors, BioVie, board of directors, Corporate governance, drug delivery platform, election, Halozyme Therapeutics, Jim Lang

Jim Lang; Halozyme Therapeutics; Board of Directors; appointment; election; Bench International; biopharmaceutical; drug delivery platform; corporate governance; OptimizeRx; BioVie

Models are out, molecules are in as AI drug startups sprint to the clinic

1 month ago talkbio0Tagged Absci, AI drug discovery, AI-designed molecules, Clinical Trials, clinical-stage AI startups, Funding, Insilico Medicine, PsiThera, Recursion Pharmaceuticals, small molecule therapeutics

AI drug discovery; AI-designed molecules; clinical-stage AI startups; small-molecule therapeutics; biotech funding; Insilico Medicine; Recursion Pharmaceuticals; Absci; PsiThera; clinical trials